JARDIANCE® provides triple protection in your patients with CRM conditions:
reduced risk of CV death
or kidney disease progression*1,2
reduced risk of CV death
or hospitalisation for heart failure†3,4
reduced risk of CV death‡5
Prof. Christoph Wanner’s take on EMPA-KIDNEY
0:52
What is a typical patient that may benefit from the EMPA-KIDNEY trial results?
0:51
How relevant is the broad patient population within EMPA-KIDNEY for a general practitioner's daily practice?
01:14
